ReviewTranslational lung cancer research2026
Integrated management of immunotherapy and radiotherapy for patients with metastatic non-small cell lung cancer: a narrative review of current landscape and future directions.
Review in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Association between prognostic nutritional index and prognosis in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis.Frontiers in nutrition · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Despite advancements in systemic therapy, metastatic non-small cell lung cancer (NSCLC) remains largely incurable. Immunotherapy, primarily immune checkpoint inhibitors (ICIs), has improved outcomes, but durable responses are confined to a subset of patients. Emerging preclinical and clinical evidence suggests that radiotherapy (RT) can potentiate antitumor immunity, transforming localized treatment into a systemic effect. This narrative review aims to synthesize current knowledge on the mechanisms and clinical applications of combining RT with immunotherapy for metastatic NSCLC, assessing its potential to improve survival. Methods: A systematic search of PubMed was conducted to identify English-language articles published between January 2010 and December 2025 on immunotherapy combined with RT for metastatic NSCLC. Key Content and Findings: This article comprehensively analyzes the synergistic mechanisms between RT and immunotherapy, including immunogenic cell death (ICD), enhanced antigen presentation, and modulation of the tumor microenvironment (TME). We critically review the clinical evidence for this combination across various disease settings: definitive treatment of the primary tumor, management of brain and adrenal metastases, and the novel strategy of multisite RT. Key considerations such as the optimal sequencing of therapies and the influence of RT dose/fractionation on efficacy and abscopal effects are discussed. Conclusions: The integration of RT with immunotherapy represents a promising therapeutic paradigm for metastatic NSCLC, demonstrating encouraging efficacy, particularly in managing thoracic disease and brain metastases. Preliminary data on targeting multiple metastatic sites are also compelling. However, critical questions regarding optimal patient selection, treatment sequencing, and ideal RT protocols remain areas of active investigation, necessitating further validation in randomized controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.